

Index

A

- α -Amino-3-hydroxy-5-methylisoxazole-4-propionate receptor, *see* AMPARs
- ACC, *see* Anterior cingulate cortex
- Acetylcholine esterase, 15, 112
- Acetylcholine receptors, 14, 183
 - inducing activity, 24
- AChE, *see* Acetylcholine esterase
- AChRs, *see* Acetylcholine receptors
- acr-16*, 56
- Acrobatic task acquisition, 352–353
- Actin binding protein, 271–272
- Actin regulatory proteins, in dendritic spines, 249–250
- Active zones, 237
 - cytomatrix at, 238–239
 - plasma membrane at, 237–238
 - precursor vesicles identification at, 239–241
- Adhesion zipper, 84
- A-ephrin genes, 151
- agrin* /*CHAT* double-knockout mice, 19
- Aggrin; *see also* ECM signaling, in synaptogenesis role in synaptogenesis, 171–172
 - structure and binding partners of, 171
- AKAP79/150, 87, 91–92
- Alzheimer's disease, 378, 393
- apposition size, changes in, 438
 - normal aging and synapse loss, 432–434
 - synaptical alterations, 434–437
 - synaptic decline in, 439–440
- AMPA receptors, 72–73, 113, 116, 168, 210, 325–327, 351, 358, 361, 365
 - GluR2 subunit, overexpression of, 264
 - transport, 214–216
- AMPA GluR1, 324
- AMPARs, *see* AMPA receptors
 - endocytosis of, 373–374, 476–478
 - GluR4-containing, 366
 - pathways for delivery of, 368–369
 - subcellular organization of, 371–373
 - synthesis of, 366
 - trafficking of, 367–368
- Amygdala
 - and fear, 381–382
 - thalamic LTP, 382
- Amyloid beta, 439
- Amyloid plaques, 431
- Anaphase promoting complex (APC), 57
- Anhedonia, 422
- Anterior cingulate cortex and behavioral fear, 384–385
 - long term potentiation in, 384
 - synaptic transmission in, 384
- APC, *see* Anaphase promoting complex
- Aplysia californica*, 30–31, 37
 - cell adhesion molecule, 98
- ApoER2, *see* Apolipoprotein E receptor 2
- apoER2/VLDL receptors, 175
- Apolipoprotein E receptor 2, 140, 174
- ApSyn, 38
- Arc, 342
- ARIA, *see* Acetylcholine receptor, inducing activity
- Asperger's syndrome, 409
- Asp-His-His-Cys motif, *see* DHHC
- Autapses, 6
- Autistic disorder, 120–121, 378, 409
 - genes, 410–414
 - model for, 412–414
 - and neuroligins, 414–416
- Autoimmune neuromuscular disorder, 172

- Autophosphorylation, 151
 Axonal pathfinding in, 5–7
 Axospinous synapses, 359
 excitatory, 350
- B**
- α -Bungarotoxin, 185
 Barrel cortex, 191
 “Basal lamina ghosts”, 15
 Bassoon, 88
 BC200, 260, 450
 BDNF, *see* Brain-derived neurotrophic factor
 Benzodiazepines, 280
 B-ephrin genes, 151–152
 BMPs, *see* Bone morphogenetic proteins
 Bone morphogenetic proteins, 58
 Brain-derived neurotrophic factor, 100, 179, 286, 340, 424, 459
 Brodmann area, 433–434
 Brownian movements, of receptors, 222–223
- C**
- δ -Catenin/NPRAP, 84
C. elegans, 24, 30, 44–45, 126
 methods for studying, 46–49
 molecular mechanisms of NMJ assembly, 53–56
 synapse development, regulatory mechanism of, 50–51, 56–61
 synaptic activity, role of, 61–62
 synaptic target recognition, 51–53
- CA1 region
 basal dendrites, 355
 pyramidal cells, 355
 stratum radiatum, 356–358
- CA3 region pyramidal neurons, *see* Neurons
- Calcium (Ca^{2+})
 -binding sites, 113
 channels, 103
 hotspots, 34
 in neuronal signaling, 334–336
- Calcium imaging, 49
- Cadherins, 288
 axonal targeting and termination, role of, 88–89
 binding function of, 84–87
 cellular and subcellular localization of, 88
 dendritic arborization, role of, 88–89
 functions in other systems, 92
 localization of, 90
 molecular mechanism of, 91–92
 in nervous system, 85
 in plasticity, role of, 90
 in pre and postsynaptic components, role of, 89–90
 in spine growth, 88–89
 structure of, 84–87
 trafficking of, 88
- Calcitonin gene related peptide, 379
- Calmodulin-dependent protein kinases, 171, 305, 324–325, 337, 339, 382
- Calyx of Held synapse, 5
- Cambridge Neuropsychological Test Automated Battery, 394
- CaMKII, *see* calmodulin-dependent protein kinases
- cAMP gating, 188
 cAMP responsive element-binding protein, 260, 305, 335, 339–340, 343, 383, 424, 426, 453
 binding protein, 92
- cAMP–PKA pathway, 39
- CAMs, *see* Cell adhesion molecules
- Cannabinoid, 461
- CANTAB, *see* Cambridge Neuropsychological Test Automated Battery
- Cargo recognition process, 201–202
 directional sorting and transport in, 202–204
 selective transport and selective retention in, 204
 as transport adaptors, 204–205
- CASK, 114, 132–133, 201, 213
- CASK/LIN2 protein, 266
- Catenins, 288
- Cavalieri principle, 355
- CAZ, *see* Cytomatrix assembled at the active zones
- CC-Homer, 269
- CD8::GFP::Sh, 47
- Cdc42, 156
 binding protein IRSp53, 270

- cdc42/rac interactive-binding motifs, 251
- Cell adhesion molecules, 51
neural, *see* Neural cell adhesion molecules
- Celsr2, 89
- Central nervous system, 84, 137, 172–173, 179, 277
synapses, 14
- Central pattern generator, 31
- c-fos gene, 172
- CGRP, *see* Calcitonin gene related peptide
- ChAT, *see* Choline acetyltransferase
- Chemoaffinity hypothesis of Sperry, 6, 138
- Choline acetyltransferase, 19
- Cholinergic preganglionic axons, 171
- Chondroitin sulfate proteoglycans, 99
- Chronic pain, 378, 385–387
- Chronic relapsing disorder, 474
- Clostridial neurotoxins, 400
- CNS, *see* Central nervous system
- collagen XVIII, 55
- Collybistin, 287
- Complexin proteins, 392
clinical data of, 399
expression in brain, 394–395
physiological functions of, 396–397
preclinical data of, 397–398
presynaptic localization of, 394
- Cortactin-binding protein, *see* Shank protein
- CP, *see* Critical period
- CPG, *see* Central pattern generator
- CPG15, 342
- CPLXII mRNA expression, 460
- CRD, *see* Cysteine-rich domain
- C-reactive protein, 167
- CREB, *see* cAMP responsive element-binding protein
- CREST, 305
- CRIB, *see* cdc42/rac interactive-binding motifs
- Critical period, 180, 189
- CRP, *see* C-reactive protein
- CSPGs, *see* Chondroitin sulfate proteoglycans
- C-terminal cadherin, 84, 88
- CYFIP1, 260, 451
- Cysteine string protein, 461
- Cysteine-rich domain, 74
- Cytomatrix assembled at the active zones, 54, 236
molecular organization of, 239
precursor formation at, 243
- Cytoplasmic dynein associates, 201
- Cytoskeleton, of dendritic spines, 156
- D**
- α -Dystroglycan, 288
- D396X, 120–122
- DAG, *see* Diacylglycerol
- D-amphetamine, 481
- Dap160, 55
- de novo* protein synthesis, 37
- Delay eyeblink conditioning, 353–354
- Dendrites, growth of arbor growth of, 299
filopodial motility of, 299–301
glutamatergic synaptic transmission, effect of, 302–303
growth in intact tissues, 298–299
neuronal growth, influences in, 301
neurotransmission-mediated, 304–306
versus synaptogenesis, 303–304
- Dendritic filopodia, 153, 299–301
- Dendritic spines actin regulatory proteins in, 249–250
myosin functions in, 206
structure of, 262–264
- Dendritogenesis, 303–304
- Depression, 378
altered synaptogenesis in, 425–428
animal models of, 421–423
defining, 420–421
pathophysiology of, 423–425
- Dexamethasone test, 422
- DGC, *see* Dystrophin glycoprotein complex
- DHHC, 74
- Diacylglycerol, 181
- Disabled (Dab-1) signaling pathway, 174
- Distal dendrites, 198
- DLC1/DLC2, 202
- DLPFC, *see* Dorsolateral prefrontal cortex
- DN-cadherin in *Drosophila*, 84
- Dorsal root ganglion, 380

- Dorsolateral prefrontal cortex, 403
 DREAM, 335
 DRG, *see* Dorsal root ganglion
Drosophila melonagaster, 24, 30, 44–45, 98, 126, 156, 249, 260
 cadherin functions in, 92
 methods for studying, 46–49
 molecular mechanisms of, *see*
 Drosophila, molecular
 mechanisms of
 Semaphorin II, 53
 synapse development genes, 50–51
Drosophila, molecular mechanisms of
 NMJ assembly, 53–56
 synapse development, regulatory
 mechanism of, 56–61
 synaptic activity, role of, 61–62
 synaptic target recognition, 51–53
Drosophila PIX, 56
Drosophila Wishful Thinking, 58
 Drug addiction, 474
 Duchenne and Becker muscular
 dystrophy, 288
dunce mutants, synaptic activity in, 100
 Dyneins, 199
 Dystroglycan, 21
 Dystrophin glycoprotein complex,
 288–289
- E**
eag Shaker, synaptic activity in, 100
 Early adverse events, 420
E-cadherin, 140
 ECM signaling, in synaptogenesis
 agrin functioning, in CNS, 20
 agrin hypothesis, 16–17
 postsynaptic differentiation, by
 agrin, 19–20
 postsynaptic signal transduction
 mechanisms, for agrin, 17–19
 ECM, *see* Extracellular matrix
 Electroconvulsive therapy, 422
 ELISA, *see* Enzyme-linked
 immunoassorbent assay
 ELKs-Rab6-interacting protein-
 CAST, 55
 Ena/VASP
 family, 250
 proteins, 156
 Endocytosis, 43
 Endoplasmic reticulum, 211
 Enzyme-linked immunoassorbent
 assay, 399, 432
 Eph receptors downstream signaling
 mechanisms, 156–159
 expression of, 153
 localization of, 153
 in morphological plasticity,
 153–154
 in regulating synaptic plasticity,
 154–155
 in spine formation, 153–154
 EphA5-Fc fusion protein, 154
 EphB receptors, 154
EphB2 allele, 155
 EphB2, 250–251
EphB2^{lacZ} knock, 155
 EphrinB–EphB receptor signaling,
 158
 Ephrins expression of, 153
 localization of, 153
 in regulating synaptic plasticity,
 154–155
 Eps8, 252
 EPSP, *see* excitatory postsynaptic
 current
 ER, *see* Endoplasmic reticulum
 ErB4, 182
 ErbB-4 receptor tyrosine kinase, 338
 ERC, *see* ELKs-Rab6-interacting
 protein-CAST
 Erf2p/Erf4p protein complex, 74
 Excitatory postsynaptic current, 4
 Exocyst complex, 371–373
 Extracellular matrix (ECM), 15; *see*
 also ECM signaling, in
 synaptogenesis
 molecules, 164
- F**
 F-actin, 71, 91
 Fas II, *see* Fasciclin II
 Fasciclin II, 51
 expression, 100
 Fasciclin III, 51
 FCS, *see* Fluorescence correlation
 spectroscopy
 FGF receptor, 99
 FGF-7, 103
 FGF-10, 103
 FGF-22, 103, 164
 Fibronectin type III-like repeats, 98

- Fick's laws, 223
 Filopodia, 249
 Fluorescence correlation spectroscopy, 224
 Fluorescence recovery after photobleaching technique, 223
 Fluorescence resonance energy transfer, 251
 FM1-43, *see* Styryl dyes
 FM4-64, *see* Styryl dyes
 FMR1 knockout mouse, 448
 FMRP, *see* Fragile X mental retardation protein
 Fragile X mental retardation 1 gene, 446
 Fragile X mental retardation protein, 254, 449–451
 mechanism of, 449–451
 Fragile X syndrome, 445
 female heterozygotes, 445
 genetics of, 446
 mGLUR theory of, 451–452
 models of, 447
 mutation 1, 412
 Fragile X-Associated Tremor/Ataxia Syndrome, 446
 FRAP, *see* Fluorescence recovery after photobleaching technique
 FRAS1, *see* Fraser syndrome 1
 Fraser syndrome 1, 265
 FRET, *see* Fluorescence resonance energy transfer
 Freund's adjuvant model, 385
 Frontal cortex, 435
 Fukuyama congenital muscular dystrophy, 25, 289
futsch mutants, 60
 FXTAS, *see* Fragile X-associated tremor/ataxia syndrome
Fyn genes, 147
- G**
 GABA neurotransmission, 55
 GABA_A receptors, 170
 functional analysis of, 281
 structure and function of, 278–280
 synaptic and extrasynaptic distributions of, 280–284
 trafficking of, 284–286
 GABA_AR γ 2L, 328–329
 GABAergic interneurons, 3
 GABAergic synapses, 3, 119, 277, 289, 328
 axosomatic, 106
 GABARAP, 284
 GAD65, *see* Glutamic acid decarboxylase, 65 kDa
 GAD67, *see* Glutamic acid decarboxylase, 67 kDa
 GAG, *see* Glycosaminoglycan
 GAL4/UAS RNAi expression system, 48
 GAP43, 204
 GDNF, 99
 GEFs, *see* Guanine nucleotide exchange factors
 Gene therapy, 453
 Gene transfer techniques, 69
 Gephyrin, 116, 141, 144, 286–287
 GFP, *see* Green fluorescent protein
 GFP-tagged NMDA receptor subunit 1, 212
 GFP-tagged transferrin receptor, 203
 GKAP, *see* Guanylate kinase associated protein
 GKAP/SAPAP proteins, 248, 262
 GluR2–GluR3 oligomers, 368
 Glutamate receptor subunit GluR1, 71
 GluR6, 89
 Glutamate transporter-1, 425
 Glutamate, 476
 Glutamate receptor interacting protein, 73, 87, 153, 155, 321–322, 327, 368
 AMPA-binding protein, 265
 Glutamic acid decarboxylase, 277–278
 65 kDa, 74, 90
 67 kDa, 403–405
 Glycine receptors, 201
 Glycosaminoglycan, 16
 GlyRs, *see* Glycine receptors
 GODZ, 285
 Golgi apparatus, 198, 211
 Golgi membranes, 74
 Green fluorescent protein, 46, 76, 141, 210
 GRIP, *see* Glutamate receptor Interacting protein
 GSK-3/Shaggy, 59
 GTP, *see* Guanosine triphosphate
 GTPase activating proteins, 250

GTPase Rab8, 369
 Guanine nucleotide exchange factors, 152, 267
 Guanosine triphosphate, 314
 Guanylate kinase associated protein, 72

H
 HAP1, 459
HdhQ, 459
 hEGF, *see* Human EGF
 HEK293 cells, 89, 115, 118, 129–130, 142, 169
Helisoma trivolvis, 30–32
Helix pomatia, 30, 36
 Heparan sulfate proteoglycans, 103
 Heparin-binding domain, 102
 Hermaphrodite-specific neurons, 47
 Heterogeneous nuclear ribonucleoproteins, 449
 Heteromeric spectrin, 100
 Heterophilic cell adhesion molecules
 Ephrins/Eph receptors, 7
 neurexins/neuroligins, 7
 High-voltage activated calcium channels, 91
 Hippocampal neurogenesis, 424
 Hippocampus and cerebellum, 186–188
 Hippocampus-dependent Morris water maze task, 354
 Homer protein families, 269–271
 Homophilic cell adhesion molecules
 cadherins, 7
 NCAM, 7
 HSNs, *see* Hermaphrodite-specific neurons
 Hsp90, 368
 HSPC300, 252
 Human EGF, 36
 Huntington's disease, 397, 453
 cortico-striatal synaptic function in, 468–469
 mouse models of, 458
 neuronal vulnerability in, 458–459
 postsynaptic dysfunction in, 462–466
 presynaptic dysfunctions in, 459–461

I
 ICDs, *see* Intracellular domains
 Ig, *see* Immunoglobulin superfamily proteins
IGSF4 gene, 126, 129
 Immobilized β -neurexin, 111
 Immunoglobulin superfamily proteins
 in synaptic differentiation, 125–126
 in synaptic formation, 126–127
 in vitro cell culture techniques, 30, 32
 Inferior parietal cortex, 436
 Inhibitory postsynaptic current, 170
 Inositol trisphosphate, 181
 Insulin receptor substrate of 53kDa, 252, 270
 Integrins, 173
 Intercellular junctions, 5
 Interference peptides, 479–482
 Internal ribosome entry site-GFP-LacZ reporter, 144
 Intracellular domains, 180, 337
 Intracellular membrane trafficking functions, 5
 Intracellular signal processing machinery, 313
 IP3, *see* Inositol trisphosphate
 IPSC, *see* Inhibitory postsynaptic current
 IRSp53, *see* Insulin receptor substrate of 53kDa

J
 JNK, *see* Jun N-terminal kinase
 Jun N-terminal kinase, 182, 202

K
 Kalirin, 251
 Kalirin-Rac1-PAK pathway, 156
 KIF17, 213–214
 KIF5A, 214
 KIFs, *see* Kinesin superfamily proteins
 Kinesin superfamily proteins, 199–200
 Kv1.4 channel, 70

L
Lama2, *see* Laminin, $\alpha 2$
Lama4, *see* Laminin, $\alpha 4$

- Lambert–Eaton myasthenic syndrome, 172
- Laminin(s)*
 $\alpha 2$, 22
 $\alpha 4$, 22
family of, 172
synaptogenetic activity of, 172–173
- Laminins; *see also* NMJ, subsynaptic architecture presynaptic differentiation, role in, 23–24
- Lateral diffusion of receptors, *see* Neurotransmitter receptor lateral diffusion, in synaptogenesis
- Lateral geniculate nucleus, 188, 301
- Left pedal dorsal 1, 35
- L-EGF, *see* *Lymnaea* EGF
- Leukemia, 453
- LGN, *see* Lateral geniculate nucleus
- LIM kinase, 252
- Liprin- α protein, 47
- Lithium chloride, 453
- LN agrin, 17
- Localized synaptic protein translation, 61
- Long-term depression, 155, 183, 263, 333, 365, 373–374
and behavioral sensitization, 475
- Long-term memory, 37
- Long-term potentiation, 90, 333, 365, 378
in cortical-amygdala pathway, 382–383
and fear, 381–382
thalamic amygdala, 382
- LPeD1, *see* Left pedal dorsal 1
- LTD, *see* Long-term depression
- LTM, *see* Long-term memory
- LTP, *see* Long-term potentiation
- L-type voltage gated calcium channels, 382
- L-VGCCs, *see* L-type voltage gated calcium channels
- Lymnaea* EGF, 36
- Lymnaea stagnalis*, 30–32, 36
- M**
- 2-Methyl-6-(phenylethynyl) pyridine, 452
- MAGUK family, *see* Membrane-associated guanylate kinase, family
- MAGUK proteins, 214, 219
- Major depressive disorder, 420
- MAP1b/*futsch* protein, 260
- MAP2, 287
- MAPK, *see* Mitogen-activated protein kinase
- MAPs, *see* Microtubule-associated proteins
- MATRICES, *see* Measurement and Treatment Research to Improve Cognition in Schizophrenia
- MDD, *see* Major depressive disorder
- Measurement and Treatment Research to Improve Cognition in Schizophrenia, 393
- Melampus*, 30
- Membrane associated guanylate kinase, 464
family, 69, 73
- MEN1*, *see* Multiple endocrine neoplasia type
- Mena, 252
- menin* expression, 37
- Mental retardation, 262, 378
- mEPSCs, *see* Miniature excitatory postsynaptic currents
- Messenger ribonuclearprotein, 449
- Metabotropic GluRs, 265
- Methylazoxymethanol acetate, 425
- mGluR antagonists, 452
- mGluRs, *see* Metabotropic GluRs
- Microtubule and actin filament based transport systems, 206
- Microtubule-associated proteins, 198
1B, 450
- Microtubule-organizing center, 198
- Miniature excitatory postsynaptic currents, 89, 460
- Miniature inhibitory postsynaptic currents, 328
- Mint-1, 114, 132–133, 201, 213
- mIPSC, *see* Miniature inhibitory postsynaptic currents
- Mitogen-activated protein kinase, 38, 56, 335, 369
phosphorylation, 101
- MLCK, *see* Myosin light chain kinase
- mLIN10-motor complex, 201
- mLIN7-receptor-vesicle complex, 201
- Molluscan models, 40–41
- mRNA, 449–451

- MSB, *see* Multiple-synapse boutons
MTOC, *see* Microtubule-organizing center
Multiple endocrine neoplasia type 1, 37
Multiple lipid modifications, 72–75
Multiple-synapse boutons, 356–357
Muscle specific kinase, 17, 55
 knockouts, 18
Muscle–eye–brain disease, 25
MuSK, *see* Muscle specific kinase
Mutant huntingtin, 458
Myc protein, 24
Myosin light chain kinase, 107, 314
Myosin Va, 206
Myristoylation, 72
- N**
 β -Neurexin, 78
Narp, 342
N-cadherin mutant fly eyes, 52
NCAM- deficient NMJs, 107
NCAM/PSA-NCAM expression, 101, 103
NCAM120, 98, 102
NCAM140, 98–100, 102
NCAM180, 98, 102
Nerve growth factor, 179
Nerve terminals, 236
Netrin receptor UNC5H, 266
Neural cell adhesion molecules, 217
 in *Aplysia*, role of, 100–101
 in *Drosophila*, role of, 100–101
 extracellular binding partners of, 98–100
 and hippocampal synaptic plasticity, 105–106
 in hypothalamo-neurohypophysial system, 106–107
 intracellular signaling mediated by, 100
 in mammalian synaptogenesis, 101–104
 polysialylation of, 100
 structure of, 98
 and transmitter release, 107–108
Neuregulin, 24
Neuregulin-1-ICD-Eos signaling, 338
Neurofibrillary tangles, 431
Neuroigin and β -neurexin complex, interaction of biochemical aspects of, 112–115
 clinical aspects of, 120–122
 at excitatory versus inhibitory synapses, 119–120
 model structure of, 115
 in synapse formation, role of, 115–119
Neuroigin-2, 289–291
Neuroligins, 217, 414–416
Neuromuscular junction, 5, 183–186
 subsynaptic architecture, *see* Neuromuscular junction, subsynaptic architecture
 synaptogenesis at, 184
Neuromuscular junction, subsynaptic architecture laminin localization, 21–22
 laminin proteins, 21
 other mechanisms, 24–25
 synaptic organization, role in, 22–23
 type I, 46
 type II, 46
Neuronal pentraxins family of, 167–168
 functions of, 168–169
 in synaptogenesis, 169
Neurons
 bitufted, 3
 CA1-region pyramidal, 2, 188
 CA3-region pyramidal, 2
 molluscan, 30
 multipolar, 3
 Rohon–Beard, 88
 types of, 2
Neuropil, 5–6
Neurotransmitter receptor lateral diffusion, in synaptogenesis experimental approaches to, 223–224
 lateral diffusion of receptors, 226–230
 with plasma membrane, 225–226
 principles of, 222–223
Neurotrophin signaling, 180–183
NF- κ B, *see* Nuclear factor κ B
NFAT, *see* Nuclear factor of activated T-cells
NG108 neuroblastoma cells, 185

- NgCAM proteins, 204
 NGF, *see* Nerve growth factor
 Nitric oxide synthase (nNOS), 267
 N-linked glycosylation, 112
 NMDA receptors, 113, 116, 210, 325–327, 335, 339–340, 351, 365–366
 trafficking of, 211–214
 trafficking and surface expression, 464–465
 NMDA-receptor dependent plasticity, 2, 451
 N-methyl-D-aspartate receptors, *see* NMDA receptors
 NMJ, *see* Neuromuscular junction
 nNOS, *see* Nitric oxide synthase
 Notch, 182
 NR2A–PSD-95/PSD-93 complex, 268
 NR2B expression, 387
 NRG1 gene, 405
 NTD, *see* N-terminal domain
 N-terminal Fes/CIP4 homology, 59
 Nuclear export signal, 449
 Nuclear factor κ B, 337
 Nuclear factor of activated T-cells, 334
 Nuclear localization signal, 449
 N-WASP, 156
- O**
 Olfactory receptor neurons, 92
 OML, *see* Outer molecular layer
 Optic tectum, 188–189
 ORNs, *see* Olfactory receptor neurons
 Outer molecular layer, 437
- P**
 α -Pcdh/CNR isoform, 140–141
 p75 pan-neurotrophin receptor, 180, 182
 PACSIN1, 461
 Paired-pulse facilitation, 382
 Palmitoylation, 285
 Palmitoyl acyl-transferases, 74
 PAM, *see* Myc protein
 PAM-highwire-rpm1, 24
 Parkinson disease, 378
 Parvalbumin-positive basket cells, 282
 PATs, *see* Palmitoyl acyl-transferases
 PC12 cells, 396
 α - and γ -Pcdh proteins, 139
 β - or γ -Pcdh isoforms, 140
Pcdh- α , - β , and - γ genes, 138–140, 145
Pcdh- γ deletion homozygotes, 143
 PDDNOS, *see* Pervasive development disorder not otherwise specified
 PDGF, *see* Platelet-derived growth factor
 Periactive zone, 44
 Pervasive development disorder not otherwise specified, 409–410
 Pervasive developmental disorders, 409
 Phosphatidylinositol 4,5-bisphosphate, 158
 PI3 kinase, 182, 369
 Piccolo–Bassoon transport vesicles, 235
 generation of, 243
 PICK1, 153, 366, 373
 Picket-barrier model, 225
 PIX/PAK/GIT1 signaling module, 251
 Platelet-derived growth factor, 100
Porc, *see* *Porcupine*
Porcupine, 74
 Porsolt swim test, 421
 Postsynaptic Density-95, 51, 69–71, 75–77, 89, 91, 105, 113, 115, 118–120, 141, 144, 204, 210–211, 217–218, 248, 253, 262, 266–270, 283, 289, 322–324, 337, 370, 414, 465
 Postsynaptic Receptor Clustering, 55
 Postsynaptic scaffold proteins
 function at synapses, 264–266, 273
 molecular interactions of, 248–249
 PP1B, 324
 PPD, *see* Pervasive developmental disorders
 PPF, *see* Paired-pulse facilitation
 PPI, *see* Prepulse inhibition
 Prepulse inhibition, 394
 Presynaptic particle web, 141
 Primordial active zones, quantal transport of, 241–243
 Proline-rich synapse-associated protein, *see* Shank protein

- Protein complexes, at excitatory synapses, 68
- Protein kinases
 and axon geometry, 315–318
 and dendrite geometry, 318–320
 glutamatergic synapses, recruitment at, 320–327
 inhibitory synapses, recruitment at, 327–329
- Protein multimerization, 69–70
- Protein palmitoylation, 72–73
- Protein phosphorylation, 73
 effects of, 323
- Protocadherin genes cloning of, 138–140
 expression and localization of, 140–142
 genetic analysis of, 142–146
 issues related to, 146–148
- protocadherin-42/Pcdh1*, 138
- protocadherin-43/Pcdh2*, 138
- Proximal dendrites, 198
- PSD molecules, 247
- PSD proteins, regulated degradation of, 255
- PSD-95, *see* Postsynaptic density 95
- PSD-95/Dlg/ZO-1 homology, 262
- ptp-3a* isoform, 52
- PTV, *see* Piccolo–Bassoon transport vesicles
- PTX3, 168
- Purkinje cell, 89, 186, 352, 356
- Purkinje cell dendrites, 156
 abnormal formation of, 303
- Q**
- QDs, *see* Quantum dots
- QPCR, *see* Quantitative polymerase chain reaction
- Quantitative polymerase chain reaction, 37
- Quantum dots, 224
- R**
- R451C, 120–122
- R6/2 HD mice, 460
- Rab 3-interacting molecule, 54, 88, 107, 243
- Rab Proteins, 371–373
- Rab5-regulated endosomes, 74
- Radioimmunoassay, 435
- rapsyn* gene, 18
 knockouts, 18
- RAS guanine nucleotide exchange factor, 265
- Ras/extracellular signal-regulated protein kinase, 339
- RasGEF, *see* RAS guanine nucleotide exchange factor
- Receptor protein tyrosine phosphatases, 52
- Red fluorescence protein, 367
- Reeler mice, 174
- Reelin
 receptors of, 174
 in synaptic maturation, 174–175
 in synaptogenesis, 174
- Retinal ganglion cells, 188, 301
- Rett syndrome, 412
- RFP, *see* Red fluorescence protein
- RGC, *see* Retinal ganglion cells
- RHO GTPases, 250–252
 divergence of pathways in, 252–253
- Ribbon synapses, 5
- Right Pedal Doral 1, 33
- RIM, *see* Rab 3-interacting molecule
- RNA interference, 48
- RNAi, *see* RNA interference
- Rohon–Beard neurons, 88
- Rohon–Beard synapses, 89
- Rostroventral medulla, 379
- RPeD1, *see* Right Pedal Doral 1
- RPTP, *see* Receptor protein tyrosine phosphatases
- RVM, *see* Rostroventral medulla
- S**
- SAD-1, 54
- SAP-102, 214, 216, 268
- SAP97, 268, 366
- SAPAP3 mRNAs, 255
- Schaffer collateral synapses, 186
- Schizophrenia, 329, 378, 392
 cognitive defects in, 393–394
 complexins in, 394–399
 other molecular markers in, 403–405
 pathophysiology of, 393
 SNAP-25 responsible for, 400–403
- Schwann cell, 23, 25
- SER, *see* Smooth endoplasmic reticulum

- Ser818, 369
 Serotonin 5-HT, 379
 Serotonin 5HTT promoter gene, 420
 Sertoli cell proliferation, 447
 SH3, *see* Src-homology-3
 Shaker-type K channels, 266
 Shank proteins, 252, 254, 262, 269–271
 Shank2/ProSAP1 mRNA, 254
 Silicon chip technologies, utilization of, 40
 Single particle tracking experiments, 224
 sJMD, 91
Ski, *see* *Skinny hedgehog*
Skinny hedgehog, 74
 S-laminins, 21
 Smooth endoplasmic reticulum, 263
 SNAP-25, 74, 392
 clinical data of, 402–403
 physiological functions of, 400–401
 preclinical data of, 401–402
 presynaptic localization of, 400
 SNARE protein Ykt6, 74
 SNARE, 394, 400, 426
 SNB::GFP, 47
 SNB-1, *see* Synaptobrevin
 SNK, 342
 South Carolina Autism Project, 410–411
 Spatial memory acquisition, 359–360
 Spinal cord dorsal horn,
 homosynaptic long term
 potentiation, 380–381
 sensory transmission by, 378–379
 serotonin (5-HT)-induced
 potentiation, 379
 synaptic potentiation in, 380
 Spinophilin, 270
 SPT, *see* Single particle tracking experiments
 Sra-1, 260
 Sra1/CYFIP1, 252
 Src-homology-3, 69
 ST8SiaII (STX) enzyme, 105
 ST8SiaIV (PST) enzyme, 105
 Stargazin protein, 114
 Stargazing, 168–169
 Stratum lacunosum-moleculare dendrites, 2
Streptococcus pneumoniae, 168
 Styryl dyes, 76, 107, 130, 243
 SVs, *see* Synaptic vesicles
 SYD-2: GFP, *see* SYNapse
 Defective::GFP fusion NMJs
 reporter
 SYG-1/SYG-2 homologs, 52
 SYNapse Defective::GFP fusion NMJs
 reporter, 46, 48
 Synapse formation, issues in; *see also*
 Synaptic components, in synapse
 formation gene transcription,
 36–37
 interspecies synaptogenesis
 between molluscan neurons,
 33–34
 in vivo regeneration, 30
 in vivo synapse formation, 40
 in vitro reconstruction of neuronal
 networks, 31
 molluscan cell culture techniques,
 31
 protein synthesis, 37
 soma–soma synapse model, 34
 synaptic hierarchy, 33
 synaptic number, regulation of, 39
 synaptic plasticity, 37–38
 synaptic scaling, regulation of, 39
 synaptogenic program, effect of, 36
 transmitter–receptor interactions, 33
 trophic factors, role of, 34–36
 Synapse number, for learning and
 memory
 acrobatic task acquisition, 352–353
 delay eyeblink conditioning, effect
 of, 353–354
 negative results and interpretations,
 354–355
 skilled reaching paradigm, effect of,
 353
 spatial memory acquisition, 354
 Synapse-associated protein 70, 90, 97,
 102
 Synapses, 447–449; *see also* Synaptic
 components of Amphids
 Defective, *see* SAD-1
 remodeling of existing, 358–361
 synapse bouton formation, effect of,
 356–358
 synapse number, effect of, 352–355
 Synapse-specific glycosylation, 25
 Synapsins, 184

- Synaptic activity, in nucleus, 340–342
- Synaptic cleft, 15, 20–21, 23, 83, 116
- Synaptic components, in synapse formation
- AMPA, 325–327
 - CaMKII, 324–325
 - NMDARs, 325–327
 - PDZ domains, 321
 - PSD-95, 322–324
 - receptor diffusion, 321
- Synaptic connectivity, 4
- in Munc18-1 deficient mice, 6
 - nature of, 5
- Synaptic cytoskeletal rearrangement, 59–61
- Synaptic plasticity and cognitive function, 466–467
- Synaptic plasticity-related gene expression, 342–343
- Synaptic proteins
- assembly of, 69–72
 - monitoring of, in live cultured neurons, 75–78
- Synaptic tagging, 343
- Synaptic vesicles, 43
- Synaptobrevin, 46
- Synaptogenesis; *see also* Synaptic components, in synapse formation
- axonal pathfinding in, 5–7
 - ECM signaling, 15–20
 - interneurons, synapsing of, 3
 - in morphologic stabilization of dendrites; *see* Dendrites, morphologic stabilization of neuronal synaptic partners, 3
 - synapse formation problem, 2–4; *see also* Synapse formation, techniques in
 - synaptic cell adhesions, 5–8
 - synaptic connections, nature of, 5
- Synapto-nuclear signaling, 337–338
- molecules controlling, 338–340
 - scaffolding proteins in, 337–338
 - transmembrane proteins in, 337–338
- Synaptophysin, 435
- SynCAM 1 molecule, 116
- domain organization of, 128–129
 - expression in vertebrate brain, 129
 - identification of, 127–128
 - motifs of, 128–129
 - in synapse formation, 129–132
 - in synapse induction, 132–133
- SynCAM family, 7, 78, 133, 164, 217, 266
- T**
- Tail suspension test, 421
- TARPs, *see* Transmembrane AMPA receptor proteins
- TCBP49, 168
- TCTEX1, 202
- Temporal cortex, 435–436
- Tenascin, 170
- in GABAergic Synapses formation, 170
 - synaptogenic activity of, 170
- Terminus arborization, 314
- Tetrodotoxin, 189, 302
- TGN, *see* Trans-Golgi-network
- Thalamic–cortical synapses, 189
- Thrombospondins family, 164
- receptors of, 165
 - in synapse formation, 165–166
 - in synapse numbers, 166–167
- Torpedo californica*, 14–15
- “Tower of London” task, 394
- Trace eyeblink conditioning, 356–358
- Trans-Golgi-network, 243
- trafficking, 369
- Transmembrane AMPA regulatory proteins, 216, 227
- role of, 370–371
- trans*-synaptic signaling, 7
- Tricyclic antidepressant, 428
- TrkB knockout mice, 187
- TrkC-IgG, 185
- TTX, *see* Tetrodotoxin
- TUNEL staining, 143
- Two-photon laser scanning microscopy, 350
- Type II PDZ-recognition motif, 112
- U**
- Ubiquitin proteasome system, 248
- Ubiquitination, 24, 56–57, 255
- uEPSCs, *see* Unitary excitatory postsynaptic currents
- UNC-104/KIF1A kinesin, 54
- unc-11/AP180*, 54
- unc-26/synaptojanin*, 54

unc-57/endophilin, 54

Unitary excitatory postsynaptic currents, 101

V

VAMP protein, 236, 394

VAMP/synaptobrevin protein, 213

VAMP2 proteins, 204

Vav2-dependent endocytosis, 157

VD4, *see* Visceral dorsal 4

Veli, 114, 213

Ventral posterior medial nucleus, 191

Vertebrate neuromuscular junction, 13
formation of, 15

Very-low-density lipoprotein receptor,
140, 174

Vesicular GABA/ glycine transporter,
278

Vesicular transport packets, 216–217

VGAT, *see* Vesicular GABA/ glycine
transporter

Visceral dorsal 4, 33, 36, 38, 40

Visual cortex, 180, 189–190, 301

VLDLR, *see* Very-low-density
lipoprotein receptor

Voltage-sensitive Ca²⁺ channels, 304
VPM, *see* Ventral posterior medial
nucleus

VSCCs, *see* Voltage-sensitive Ca²⁺
channels

W

WASP proteins, 250

WAVE/Scar proteins, 252, 260

Wisconsin Card Sort Task, 394

Wnt and BMP Signaling

in *C. elegans*, 57–59

in *Drosophila*, 57–59

X

Xenopus C-cadherin, 84

Xenopus laevis, 298, 302

Xenopus nerve–muscle co-cultures,
183–184

Xenopus oocytes, 284

X-linked Asperger syndrome, 412

X-linked mental retardation, 255–257

Y

YAC72 mice, 461, 463